Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities
C Lu, D Rong, B Zhang, W Zheng, X Wang, Z Chen… - Molecular cancer, 2019 - Springer
Incidence of hepatocellular carcinoma (HCC) is on the rise due to the prevalence of chronic
hepatitis and cirrhosis. Although there are surgical and chemotherapy treatment avenues …
hepatitis and cirrhosis. Although there are surgical and chemotherapy treatment avenues …
[HTML][HTML] The role of MicroRNAs in hepatocellular carcinoma
X Xu, Y Tao, L Shan, R Chen, H Jiang, Z Qian… - Journal of …, 2018 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is one of the most common cancers, leading to the second
cancer-related death in the global. Although the treatment of HCC has greatly improved over …
cancer-related death in the global. Although the treatment of HCC has greatly improved over …
Aberrant LYZ expression in tumor cells serves as the potential biomarker and target for HCC and promotes tumor progression via csGRP78
Z Gu, L Wang, Q Dong, K Xu, J Ye… - Proceedings of the …, 2023 - National Acad Sciences
Hepatocellular carcinoma (HCC) takes the predominant malignancy of hepatocytes with
bleak outcomes owing to high heterogeneity among patients. Personalized treatments …
bleak outcomes owing to high heterogeneity among patients. Personalized treatments …
Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers
F Fondevila, C Méndez-Blanco… - … & molecular medicine, 2019 - nature.com
Regorafenib is a sorafenib-derived chemotherapy drug belonging to the multikinase
inhibitor family. This agent effectively targets a wide range of tyrosine kinases involved in …
inhibitor family. This agent effectively targets a wide range of tyrosine kinases involved in …
[HTML][HTML] Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy
Hepatocellular carcinoma (HCC) is one of the deadliest cancers due to its complexities,
reoccurrence after surgical resection, metastasis and heterogeneity. In addition to sorafenib …
reoccurrence after surgical resection, metastasis and heterogeneity. In addition to sorafenib …
Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma therapy
RY Zhang, D Wei, ZK Liu, YL Yong, W Wei… - Frontiers in Cell and …, 2019 - frontiersin.org
Chimeric antigen receptor T cell (CAR-T) therapy to hematological malignancies has
demonstrated tremendous clinical outcomes. However, the therapeutic efficacy of CAR-T …
demonstrated tremendous clinical outcomes. However, the therapeutic efficacy of CAR-T …
TRP channels in digestive tract cancers
P Stokłosa, A Borgström, S Kappel… - International journal of …, 2020 - mdpi.com
Cancers of the digestive tract are among the most prevalent types of cancer. These types of
cancers are often diagnosed at a late stage, which results in a poor prognosis. Currently …
cancers are often diagnosed at a late stage, which results in a poor prognosis. Currently …
Theranostic micelles based on upconversion nanoparticles for dual-modality imaging and photodynamic therapy in hepatocellular carcinoma
Y Han, Y An, G Jia, X Wang, C He, Y Ding, Q Tang - Nanoscale, 2018 - pubs.rsc.org
Hepatocellular carcinoma (HCC) is frequently metastatic once diagnosed and less likely to
respond to curative surgery, emphasizing the need for the development of more sensitive …
respond to curative surgery, emphasizing the need for the development of more sensitive …
HMGB1 Promotes Resistance to Doxorubicin in Human Hepatocellular Carcinoma Cells by Inducing Autophagy via the AMPK/mTOR Signaling Pathway
J Li, W Zhou, Q Mao, D Gao, L Xiong, X Hu… - Frontiers in …, 2021 - frontiersin.org
Chemoresistance remains as a major hindrance in the treatment of hepatocellular
carcinoma (HCC). High mobility group box protein 1 (HMGB1) enhances autophagic flux …
carcinoma (HCC). High mobility group box protein 1 (HMGB1) enhances autophagic flux …
Adoptive cell transfer therapy for hepatocellular carcinoma
R Zhang, Z Zhang, Z Liu, D Wei, X Wu, H Bian… - Frontiers of …, 2019 - Springer
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. This
malignancy is associated with poor prognosis and high mortality. Novel approaches for …
malignancy is associated with poor prognosis and high mortality. Novel approaches for …